TPI Enterprises buys Vistin opiates assets and confirms Portugal plant plan

By Gareth Macdonald contact

- Last updated on GMT

iStock/aniszewski
iStock/aniszewski

Related tags: Morphine

TPI Enterprises has bought Vistin Pharma ASA’s opiates and tabletting division for A$25.4m ($201.m) in a deal designed to expand the firm beyond its narcotic raw materials business.

The acquisition will see Melboure, Australia TPI take possession of a Vistin’s facility in Kragero, Norway. The site has capacity to make active pharmaceutical ingredients (API) – including codeine phosphate and pholcodine – as well is finished dosage forms.

TPI said buying the assets was part of its strategy of bolting “downstream” production capability to its existing narcotic raw material business to increase its profits.

The firm also said it plans to build an API manufacturing facility in Portugal, but declined to provide further information when contacted by in-Pharmatechnologist.com.

According to reports​ in the Portuguese press TPI has signed contracts worth €13m with poppy growers in the country in recent years.

Business expansion

TPI has been working to diversify its revenue since 2014​ when it announced its intention relocate its poppy straw processing operation in Cressy, Tasmania to a larger site on the Australian mainland.

Since then the firm has announced a number of major supply contracts. In August​ last year, it announced it had signed a deal worth $30m with an unnamed global pharmaceutical company.

In November​ TPI signed and manufacturing and supply deal with Sterling Pharma Solutions Ltd to manufacture and sell codeine phosphate in the UK.

Earlier this month TPI and Sterling signed a second supply contract. TPE said that both deals combined mean it will be supplying 20% of the 60 tonnes of codeine phosphate used in the UK each year.

Related news

Show more

Related products

show more

How to resolve sticking issues in tablet production

How to resolve sticking issues in tablet production

I Holland Limited - Tabletting Science | 24-Jun-2019 | Case Study

Tablet sticking is one of the most common problems in tablet manufacture. Find out how I Holland used the TSAR scientific predictive model and expert tablet...

The battle of performance in pharma production

The battle of performance in pharma production

Telstar Life Science Solutions | 26-Mar-2019 | Case Study

Telstar case study. Discover how a versatile freeze-dryer automatic loading & unloading systemDiscover how a versatile freeze-dryer automatic loading...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Related suppliers